_{^{<dd id='4noli'><tbody id='4noli'><td id='4noli'><optgroup id='4noli'><strong id='4noli'></strong></optgroup><address id='4noli'><ul id='4noli'></ul></address><big id='4noli'></big></td><table id='4noli'></table></tbody><pre id='4noli'></pre></dd><span id='4noli'><b id='4noli'></b></span>}}


<dfn id='4noli'><optgroup id='4noli'></optgroup></dfn><tfoot id='4noli'><bdo id='4noli'><div id='4noli'></div><i id='4noli'><dt id='4noli'></dt></i></bdo></tfoot>

_{<fieldset id='4noli'></fieldset>}

BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) to Mosunetuzumab and Cevostamab.
Mosunetuzumab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit with a dissociation constant (KD) of 2.37E-09M.
Cevostamab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit with a dissociation constant (KD) of 9.48E-10M.

Left Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Mosunetuzumab to Human CD3 Epsilon. Coating antigen: Mosunetuzumab, 1 µg/mL.
Human CD3 Epsilon final concentration: 12.5 ng/mL.
Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

Right Figure: Anti-Mosunetuzumab Antibodies inhibit the binding of Cevostamab to Human CD3 Epsilon. Coating antigen: Cevostamab, 1 µg/mL.
Human CD3 Epsilon final concentration: 7 ng/mL.
Anti-Mosunetuzumab antibody dilutions start from 30 μg/mL.
MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) exhibited non-inhibitory properties, whereas both MonoRab™ Anti-Mosunetuzumab Antibody (4G6), mAb, Rabbit (GenScript, A02290) and MonoRab™ Anti-Mosunetuzumab Antibody (38A10), mAb, Rabbit (GenScript, A02291) demonstrated significant inhibitory properties.

Left Figure: Standard Curve of Mosunetuzumab Sandwich ELISA by A02292 (10D5) and Anti-Human IgG Fc Antibody
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) was coated at a concentration of 1 μg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) as a detection antibody at a concentration of 0.2 μg/mL. MRD was as 1:5.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99993. The typicaldynamic range of the assay is 10 - 650 ng/mL. Right Figure: Standard Curve of Cevostamab Sandwich ELISA by A02292 (10D5) and Anti-Human IgG Fc Antibody
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) was coated at a concentration of 1 μg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) as a detection antibody at a concentration of 0.2 μg/mL. MRD was as 1:5.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.999. The typicaldynamic range of the assay is 2 - 150 ng/mL.

MRD Analysis of the Detection of Mosunetuzumab or Cevostamab in Biological Matrix.
The MRD is the minimum dilution necessary for the detection of Mosunetuzumab or Cevostamab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:5.
In this Sandwich ELISA assay, MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit (GenScript, A02292) was coated at a concentration of 1 μg/mL, and Mouse Anti-Human IgG Fc Antibody (50B4A9)[HRP], mAb (GenScript, A01854) as a detection antibody at a concentration of 0.2 μg/mL.

MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit

This product is specific for Mosunetuzumab and Cevostamab.

产品编号	A02292
规格	40 μg 大单询价
数量
价格	￥1980


联系黄金城集团

产品概述

Specificity	This product is specific for Mosunetuzumab and Cevostamab.
Host Species	Rabbit
Immunogen	Mosunetuzumab
Conjugate	Unconjugated

应用指导

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

Application	Recommended Usage
Sandwich ELISA	0.5-2 μg/ml
ELISA	0.01-1 µg/ml

产品属性

Form	Lyophilized
Storage Buffer	Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable for up to 1 year at -20 °C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.
Purification	Protein A affinity column
Isotype	Rabbit IgG, κ
Clonality	Monoclonal
Clone ID	10D5
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

图例

技术背景

Target Background

Mosunetuzumab is an innovative bispecific antibody that has a structure that resembles a natural human antibody, with two 'Fab' regions. However, it differs from naturally-occurring antibodies as one 'Fab' region targets CD20 and the other targets CD3. By recognizing and binding to these two different targets, Mosunetuzumab is able to redirect the cytotoxic activity of T-cells towards cancerous B-cells. This unique mechanism of action holds great potential for enhancing the effectiveness of cancer treatment.
Cevostamab (BFCR4350A) is an innovative bispecific antibody, designed to engage T-cells and myeloma cells by targeting FcRH5 and CD3 receptors, respectively. Cevostamab possesses a unique structure with two 'Fab' regions, with one specifically targeting FcRH5 and the other targeting CD3. This dual targeting mechanism activates the patient's own T-cells and redirects them to eliminate myeloma cells expressing FcRH5 by releasing cytotoxic proteins.

Synonyms

Mosunetuzumab；MOSUNETUZUMAB；Mosunetuzumab-axgb；BTCT-4465A；BTCT 4465A；Lunsumio；RG 7828；RO7030816；Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody；
Cevostamab；CEVOSTAMAB；BFCR 4350A; RG 6160; RO 7187797；Anti-FCRH5/CD3 BiTE Antibody

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

黄金城集团

MonoRab™ Anti-Mosunetuzumab Antibody (10D5), mAb, Rabbit

资源中心

技术支持

关于黄金城集团